Lopinavir: Clinical Trials

61 trials of Lopinavir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

40 completed, 9 terminated, 6 unknown, 3 recruiting. 61 Phase 2, 13 Phase 3, 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 261Completed 40, Terminated 9, Unknown 6, Recruiting 3, Withdrawn 3
Phase 313Completed 7, Unknown 4, Terminated 2
Phase 16Completed 3, Recruiting 2, Terminated 1

Follow Lopinavir: new trials by email Literature Review of Lopinavir trials Research Report on Lopinavir

Trials (filtered) newest first · largest first

All 61 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)
Lopinavir / ritonavir - Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
Phase 2RecruitingDaré Bioscience, Inc.1182026-07-172026-11-06
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DB-1311, Lopinavir and Ritonavir Tablets, itraconazole - Advanced Solid Tumors
Phase 1 / Phase 2RecruitingDualityBio Inc.8622023-08-172026-10-21
Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year
Lopinavir/Ritonavir, Placebo Administration, Questionnaire Administration - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Phase 2WithdrawnOHSU Knight Cancer Institute2021-05-012021-04-26
Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial
Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet, Telmisartan 40Mg Oral Tablet, Atorvastatin 20 Mg Oral Tablet - COVID-19, COVID-19 Drug Treatment
Phase 2 / Phase 3CompletedANRS, Emerging Infectious Diseases2942020-11-272024-12-27
FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals
Favipiravir, Lopinavir/ Ritonavir, Favipiravir Placebo - COVID-19
Phase 2CompletedUniversity College, London2402020-09-242022-12-15
the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19
High dose Interferon-beta 1a, Lopinavir/Ritonavir, Low dose Interferon-beta 1a - Covid19
Phase 2UnknownShahid Beheshti University of Medical Sciences1002020-08-202020-08-20
A Study of Combination Therapies to Treat COVID-19 Infection
hydroxychloroquine, Azithromycin, Ritonavir - COVID, COVID-19
Phase 2WithdrawnProgenaBiome2020-07-012021-04-08
Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19
Lopinavir/Ritonavir 400 mg/100 mg, Placebo - COVID-19
Phase 2CompletedVanderbilt University Medical Center4522020-06-012024-02-28
Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.
Baricitinib - Pharmacological Action
Phase 2 / Phase 3UnknownHospital of Prato2002020-05-162020-04-22
An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19
Favipiravir, Standard of Care - COVID-19
Phase 2 / Phase 3UnknownChromis LLC3302020-04-232020-06-16
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
Chloroquine or Hydroxychloroquine, Lopinavir/Ritonavir, Best standard of care - COVID-19
Phase 2 / Phase 3UnknownMedical University of Vienna5002020-04-162021-03-02
Treatment for COVID-19 in High-Risk Adult Outpatients
Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin - COVID-19, SARS-CoV-2
Phase 2 / Phase 3TerminatedUniversity of Washington2892020-04-162022-08-08
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
Hydroxychloroquine, Lopinavir / Ritonavir, Interferon Beta-1A - COVID-19
Phase 2CompletedShahid Beheshti University of Medical Sciences602020-04-092020-05-05
Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19
Levamisole Pill + Budesonide+Formoterol inhaler, Lopinavir/Ritonavir + hydoxychloroquine - COVID-19
Phase 2 / Phase 3UnknownFasa University of Medical Sciences302020-04-042020-04-13
Baricitinib Therapy in COVID-19
Baricitinib 4 MG Oral Tablet - COVID, Pneumonia
Phase 2 / Phase 3CompletedFabrizio Cantini122020-03-162020-04-24
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
Lopinavir/ritonavir, Hydroxychloroquine sulfate - COVID-19
Phase 2TerminatedAsan Medical Center652020-03-112020-05-27
Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment
Lopinavir/ritonavir, Ribavirin, Interferon Beta-1B - Novel Coronavirus Infection
Phase 2CompletedThe University of Hong Kong1272020-02-102020-04-15
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19
Wharton's jelly derived Mesenchymal stem cells., Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) - Acute Respiratory Distress Syndrome
Phase 1 / Phase 2TerminatedBioXcellerator62020-01-132024-08-27
First-Line Treatment for HIV-2
Tenofovir + Emtricitabine or Lamivudine + Zidovudine, Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir, Tenofovir + Emtricitabine or Lamivudine + Raltegravir - HIV-2 Infection
Phase 2 / Phase 3CompletedANRS, Emerging Infectious Diseases2102016-01-262019-07-22
Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection
Raltegravir, Lopinavir/Ritonavir - HIV, Pregnancy
Phase 2 / Phase 3TerminatedFundação Bahiana de Infectologia332015-06-012024-10-15

Showing 20 of 61. Sign in to see all of them.

Conditions studied

HIV Infections (34)  ·  COVID-19 (13)  ·  Coronavirus Infections (3)  ·  Infections (3)  ·  Acquired Immunodeficiency Syndrome (2)  ·  Hepatitis C (2)  ·  Tuberculosis (2)  ·  Astrocytoma (1)  ·  Brain Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Coinfection (1)  ·  Directly Observed Therapy (1)  ·  Disease Progression (1)  ·  Ependymoma (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (13)  ·  Abbott (5)  ·  ANRS, Emerging Infectious Diseases (3)  ·  Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (3)  ·  The HIV Netherlands Australia Thailand Research Collaboration (3)  ·  ViiV Healthcare (3)  ·  French National Agency for Research on AIDS and Viral Hepatitis (2)  ·  Shahid Beheshti University of Medical Sciences (2)  ·  Asan Medical Center (1)  ·  BioXcellerator (1)  ·  Boehringer Ingelheim (1)  ·  Case Comprehensive Cancer Center (1)  ·  Chromis LLC (1)  ·  Daré Bioscience, Inc. (1)  ·  DualityBio Inc. (1)

Countries

United States (29)  ·  South Africa (8)  ·  Puerto Rico (7)  ·  Thailand (6)  ·  Canada (5)  ·  Brazil (4)  ·  France (4)  ·  Italy (4)  ·  Malawi (4)  ·  Uganda (4)  ·  Argentina (3)  ·  Germany (3)  ·  Haiti (3)  ·  Kenya (3)  ·  Tanzania (3)

Top investigators

Kiat Ruxrungtham, MD (2)  ·  Alfredo Hernandez-Ruiz, MSc (1)  ·  Andrea Thurman, MD (1)  ·  Andrew Wiznia, MD (1)  ·  Ann J. Melvin, MD, MPH (1)  ·  Anthony D Harries, MD, PhD (1)  ·  Avy Violari, MD (1)  ·  Barbara A da Silva, M.D. (1)  ·  Barbara da Silva, M.D. (1)  ·  Behnam Rahimi, M.D (1)  ·  Bernd Jilma, MD (1)  ·  Carlos Brites, MD, PhD (1)  ·  Charles Flexner, MD (1)

Results publications

PMID 34473343, PMID 16962381, PMID 18540803, PMID 18625762, PMID 18647794, PMID 19008157, PMID 19237646, PMID 19512937, PMID 19597072, PMID 19729375, PMID 20192725, PMID 20554983, PMID 20842042, PMID 20942667, PMID 21124227, PMID 21266910, PMID 22144539, PMID 22180621, PMID 22293065, PMID 22716976, PMID 23300238, PMID 23766338, PMID 24086319, PMID 24180000, PMID 25037041, PMID 25222305, PMID 25406657, PMID 25838291, PMID 26482301, PMID 26684818, PMID 26977746, PMID 27439527, PMID 27516476, PMID 29189677, PMID 29767684, PMID 30102656, PMID 30968368, PMID 32321635, PMID 32401715, PMID 32493468, PMID 32555385, PMID 32618282, PMID 32738928, PMID 32770240, PMID 33106183, PMID 33681731, PMID 33685502, PMID 33850184, PMID 34224994, PMID 34693933

NIH funding

U01AI068636 (3), 2009 (1), U01AI064002 (1), U01AI068632 (1), UM1AI068616 (1), UM1AI068632 (1), UM1AI106716 (1)